We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Aclaris Therapeutics (ACRS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Aclaris Therapeutics is a member of our Medical group, which includes 1025 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Aclaris Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ACRS' full-year earnings has moved 21.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, ACRS has returned 31.4% so far this year. Meanwhile, the Medical sector has returned an average of 7.3% on a year-to-date basis. This means that Aclaris Therapeutics is outperforming the sector as a whole this year.
Adma Biologics (ADMA - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 200.4%.
For Adma Biologics, the consensus EPS estimate for the current year has increased 18% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, Aclaris Therapeutics is a member of the Medical - Drugs industry, which includes 181 individual companies and currently sits at #103 in the Zacks Industry Rank. On average, this group has lost an average of 2.4% so far this year, meaning that ACRS is performing better in terms of year-to-date returns.
In contrast, Adma Biologics falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 500 stocks and is ranked #83. Since the beginning of the year, the industry has moved 0%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Aclaris Therapeutics and Adma Biologics as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Aclaris Therapeutics (ACRS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Aclaris Therapeutics is a member of our Medical group, which includes 1025 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Aclaris Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ACRS' full-year earnings has moved 21.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, ACRS has returned 31.4% so far this year. Meanwhile, the Medical sector has returned an average of 7.3% on a year-to-date basis. This means that Aclaris Therapeutics is outperforming the sector as a whole this year.
Adma Biologics (ADMA - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 200.4%.
For Adma Biologics, the consensus EPS estimate for the current year has increased 18% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, Aclaris Therapeutics is a member of the Medical - Drugs industry, which includes 181 individual companies and currently sits at #103 in the Zacks Industry Rank. On average, this group has lost an average of 2.4% so far this year, meaning that ACRS is performing better in terms of year-to-date returns.
In contrast, Adma Biologics falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 500 stocks and is ranked #83. Since the beginning of the year, the industry has moved 0%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Aclaris Therapeutics and Adma Biologics as they could maintain their solid performance.